NGeneBio will participate in the conference of the Korean Society of Diagnostic Genetics, which will be held at the Grand Swiss Hotel in Seoul from June 1 to June 2.

During this conference, NGeneBio will focus on showcasing HEMEaccuTest™, a precision diagnostic product for blood cancer based on NGS (Next-Generation Sequencing) technology. HEMEaccuTest™ detects over 100 genetic mutations related to hematological malignancies, supporting individual patients in making optimal treatment and therapy selection. This innovative product is applicable to various blood cancer types, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), multiple myeloma (MM), and lymphoma.

NGeneBio continues to expand into various areas of the diagnostic field through the continuous commercialization and expansion of core technologies. They have achieved notable results in companion diagnostics (CDx) related to anticancer drugs, disease prognosis and prediction through liquid biopsies, and infectious disease diagnostics, expanding their technology and business.